Cytokinetics, Incorporated (CYTK)
NEUTRALFundamental
32
मूल्य
$77.95
मार्केट कैप
$10.70B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
बैलेंस शीट और तरलता
राजस्व
$68M
पिछले 12 महीने (30/6/2026 तक)
शुद्ध आय
$-894M
पिछले 12 महीने (30/6/2026 तक)
Free Cash Flow
$-535M
कुल इक्विटी
$-660M
कुल देनदारियाँ
$2.08B
Current Ratio
6.66
Interest Coverage
13.43
Debt/EBITDA
-
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$65.59
वर्तमान मूल्य
$77.95
Margin of Safety
-18.8%
Fair Value सीमा
$42.64 - $88.55
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
-
ROE
119.0%
P/B Ratio
-
P/FCF
-
Gross Margin
-
ROIC
-32.1%
लाभप्रदता Radar
Value Creation (Economic Moat)
ROIC
-32.1%
WACC
8.0%
ROIC − WACC
-40.1 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental विश्लेषण मानदंड
पास (6)
- Price CAGR 20.26%
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Revenue Growth 5Y 9.6%
- Analyst Consensus 89% Buy
फेल (11)
- EPS shows upward trend
- ROIC -32.1%
- Operating Margin -1046.1%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Overvalued)
- ROE -131.2%
- Earnings Surprise avg -12.0%
- Share Dilution 7.1%
- Net Margin Trend -1321.1% vs -707.2%
- Piotroski F-Score 2/9
अनुपलब्ध (10)
- Gross Margin NaN%
- P/FCF NaN
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
गंभीर वित्तीय चिंताएं
Earnings गुणवत्ता
निम्न गुणवत्ता: accounting की जांच करें
शेयर Dilution
नए शेयर जारी कर रही है, स्वामित्व को कम कर रही है
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. Robert I. Blum | CEO, President & Director | 61 |
| Mr. Sung H. Lee | EVP & CFO | 55 |
| Mr. Jeffrey J. Hessekiel J.D. | Executive VP, Chief Legal & Administrative Officer | 56 |
| Dr. Fady Ibraham Malik FACC, M.D., Ph.D. | Executive Vice President of Research & Development | 61 |
| Mr. Andrew M. Callos | Executive VP & Chief Commercial Officer | 56 |
| Dr. James H. Sabry M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | 67 |
| Dr. James A. Spudich Ph.D. | Co-Founder & Member of Scientific Advisory Board | 83 |
| Mr. Jeff Lotz | Vice President of Sales & Operations | - |
| Ms. Holly Laughlin | VP of Accounting & Corporate Controller | - |
| Mr. Steven M. Cook J.D. | Senior Vice President of Global Supply Chain Operations & Technical Operations | 66 |
Audit जोखिम
5
बोर्ड जोखिम
3
मुआवजा जोखिम
8
शेयरधारक अधिकार जोखिम
7
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
Latest News
Recent headlines for CYTK, sourced from Markets Gazette.
- 3/9/2026POSITIVECytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market
A significant insider transaction at Cytokinetics Inc. has been reported, with an executive exercising stock options valued at over $920,000. This occurs as the company's cardiac drug candidate progresses towards market entry. The exercise of options by an insider often signals confidence in the company's future prospects and the value of its stock. Coupled with the impending market launch of a key therapeutic, this event suggests positive momentum for Cytokinetics, potentially attracting further investor interest and supporting share price appreciation.
- 2/24/2026NEUTRALCytokinetics (CYTK) Q4 2025 Earnings Transcript
The financial community is keenly awaiting the Q4 2025 earnings transcript from Cytokinetics (CYTK). While specific details are not yet available, the analysis of such documents is crucial for investors looking to assess the biopharmaceutical company's operational performance and future prospects. Transcripts offer direct insights into management discussions regarding financial results, drug pipeline advancements, and growth strategies. Analysts will closely monitor any indications concerning key drugs like omecamtiv mecarbil or aficamten, as well as projections for the current fiscal year. The current lack of specific data suggests a cautious approach, but the release is a standard event providing transparency and a basis for informed decisions.
via Markets Gazette